Vis enkel innførsel

dc.contributor.authorMjønes, Patricia
dc.contributor.authorNordrum, Ivar Skjåk
dc.contributor.authorQvigstad, Gunnar
dc.contributor.authorSørdal, Øystein Finset
dc.contributor.authorRian, Liselotte Linnea Mårtensson
dc.contributor.authorWaldum, Helge
dc.date.accessioned2018-02-05T12:45:58Z
dc.date.available2018-02-05T12:45:58Z
dc.date.created2017-02-27T09:02:21Z
dc.date.issued2017
dc.identifier.citationAPMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 2017, 125 (3), 213-222.nb_NO
dc.identifier.issn0903-465X
dc.identifier.urihttp://hdl.handle.net/11250/2482667
dc.description.abstractThe aim of the study was to investigate the expression of erythropoietin and neuroendocrine markers in clear cell renal cell carcinoma (CCRCC). We retrospectively reviewed the medical records and re-evaluated histopathological specimens of 33 patients with CCRCC and compared with those of 11 cases of non-CCRCC. All patients were treated with a partial or radical nephrectomy at St. Olavs Hospital, Trondheim University Hospital, between 2010 and 2016. Thirty-three patients who were diagnosed with CCRCC had a total of 35 tumours, where 34 of the tumours were CCRCC and one was papillary adenoma. Thirty-three (97%) of 34 CCRCCs were positive for erythropoietin, and the same 33 (97%) tumours demonstrated strong expression for neuron-specific enolase (NSE). Two (6%) of 34 CCRCCs had a positive reaction for synaptophysin, and three (9%) of 34 were positive for CD56. Erythropoietin and NSE were negative in non-CCRCCs, and chromogranin A was negative in all tumours. The above findings suggest that there is a strong association between CCRCC and the expression of erythropoietin and NSE.nb_NO
dc.language.isoengnb_NO
dc.publisherWileynb_NO
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleExpression of erythropoietin and neuroendocrine markers in clear cell renal cell carcinomanb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber213-222nb_NO
dc.source.volume125nb_NO
dc.source.journalAPMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementumnb_NO
dc.source.issue3nb_NO
dc.identifier.doi10.1111/apm.12654
dc.identifier.cristin1454058
dc.description.localcode© 2017 The Authors APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Medical Microbiology and Pathology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs Licensenb_NO
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextpreprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal